



































1ynamics of Nitroglycerin-induced Exhaled Nitric Oxide
fter Lung Transplantation: Evidence of Pulmonary
icrovascular Injury?
anos Gal, MD, PhD,a,b Tamas Kovesi, MD, PhD,b David Royston, FRCA,b and Nándor Marczin, MD, PhDa,b
ackground: In search of real-time molecular correlates to ischemia–reperfusion-induced lung injury, we
explored the hypothesis that liberation of nitric oxide (NO) into exhaled breath after pulmonary
microvascular bioconversion of nitroglycerin (GTN) is attenuated in clinical lung transplantation.
ethods: Exhaled NO was measured under basal conditions and after intravenous administration of GTN in
patients undergoing lung transplantation. Patients undergoing routine cardiac surgery served as
controls. Basal and GTN-induced exhaled NO was also measured in donors before retrieval and after
implantation in recipients.
esults: The characteristic GTN-induced exhaled NO response observed in cardiac surgical patients before
cardiopulmonary bypass and in lung transplant and multiple-organ donors was nearly totally
abolished in lung transplant recipients. This response was also attenuated to a lesser degree in the
routine cardiac surgery patients after cardiopulmonary bypass.
onclusions: These results suggest a graded influence of time-factored complete and partial ischemia on GTN-induced
evolution of NO into exhaled breath, providing biochemical evidence for a degree of microvascular
injury, which can be monitored non-invasively at the bedside. J Heart Lung Transplant 2007;26:1300–5.
























the high incidence of characteristic histologic features
f diffuse alveolar damage in transbronchial biopsies,
he prevalence of severe allograft dysfunction termed
primary graft failure,” and the high early mortality after
ung transplantation all suggest that the current practice
f lung transplantation inflicts severe damage to the
ungs judged as “ideal” for transplantation.1–3 This
amage is difficult to predict with the current accep-
ance criteria and monitoring is currently centered on
unctional consequences on gas exchange and lung
echanics. The tremendous progress made on the
asic science of lung ischemia/reperfusion (I/R) injury
ow offers additional novel approaches for molecular
iagnostics at the bedside and therapeutic break-
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300hroughs targeting these molecular players in the clini-
al arena.4,5
NO is undoubtedly one of the master regulators of
early all aspects of pulmonary microvascular function
rom vasodilation to lymphocyte kinetics.6,7 Characteristic
hanges have been uncovered in the activities of the
O–cGMP axis in association with the development of
/R injury, and several strategies to preserve this pathway
ave shown substantial organ protection in model sys-
ems8–10 and clinical benefit in humans.11–13 However,
ecent failures of inhaled NO therapy to prevent and treat
eperfusion injury in the clinical setting may suggest that
ur understanding of NO dysfunction at the bedside is
ncomplete and perhaps some of our therapeutic strate-
ies may be flawed.14,15
Analysis of NO in exhaled breath is a powerful
on-invasive approach in molecular assessment of lung
etabolism. For instance, exhaled NO in asthma is now
ell recognized both by regulatory authorities and
ajor respiratory societies, thereby changing diagnos-
ics, monitoring and treatment.16,17 Similar “inflam-
ometry” focusing on this important “gasotransmitter”
n mechanically ventilated patients has also been pro-
osed,18,19 based on the notion that exhaled NO re-
ects the dynamism of NO production and consump-
ion in the lung.20–22
We have previously explored the influence of lung
ransplantation on exhaled NO and also proposed a
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Volume 26, Number 12ary microvasculature based on liberation of NO to
lveolar air during pulmonary metabolism of intrave-
ous nitroglycerin.18,23 We have also established the
nfluence of a clinical form of relatively short and
ncomplete lung ischemia–reperfusion injury on both
asal and GTN-induced exhaled NO, such as that occur-
ing during routine cardiac surgery, utilizing cardiopul-
onary bypass (CPB).24 In this study we sought to
stablish the influence of more prolonged and total lung




he study design included two separate studies. The
bjective of the first study was to characterize GTN-
nduced exhaled NO in lung transplant recipients.
atients undergoing routine cardiac operations utilizing
PB served as controls.
The second phase of the study targeted measurements
oth in the donors at a distant hospital before organ
rocurement and, subsequently, in the recipient after
mplantation of the same lungs after reperfusion. The
tudy was conducted in accordance with the guidelines
pproved by the ethics committee of our institution and
nformed consent was obtained from the participants.
atients
haracteristics of the control patient population and
heir anesthetic and surgical management have been
escribed previously.24 This group consisted of 10
atients undergoing myocardial revascularization (cor-
nary artery bypass grafting; CABG) with CPB.
The lung transplant group included 10 patients
ndergoing heart–lung transplantation or sequential
ilateral lung transplantation for end-stage lung dis-
ase due to cystic fibrosis or pulmonary hyperten-
ion. Lungs were procured from cadaveric donors
mean age 30 years, 8 men and 2 women) with either
raumatic head injury, sub-arrachnoidal hemorrhage
r brain tumor. The main preservation technique was
ore cooling. A complete cardiac team and necessary
erfusion equipment were deployed to the distant
onor hospital. After full heparinization, the donor
as placed on CPB and cooled to 10°C. The lungs
ere also cooled by topical ice during the cooling
eriod, and were procured without any further flush
erfusion. Total ischemia time was 214  18 min-
tes. One recipient fulfilled the clinical criteria of
rimary graft dysfunction and subsequently devel-
ped sepsis and had a protracted ICU stay. The
aO2/FIO2 ratio on admission to the ICU for the cohort
as 357  60 mm Hg. dhemiluminescence Analysis of NO and Data Analysis
reath-to-breath measurements of NO concentrations in
he lower airways were performed using a real-time,
omputer-controlled, integrated system (Series 2000 and
000; Logan Research, Ltd.) with ventilation standardized
or inspired gas (100% O2), tidal volume (5 ml/kg), respi-
atory rate (10/min) and inspiratory:expiratory ratio (1:3),
ith positive end-expiratory pressure (PEEP) at zero for
he duration of the measurement epoch, as described
lsewhere.18,24,25 Statistical comparison among the
roups was performed using analysis of variance (ANOVA)
nd Student–Neuman–Keuls post hoc tests. Statistical sig-
ificance was accepted at p  0.05.
ESULTS
hemiluminescence analysis of exhaled NO in most
entilated patients revealed a characteristic breath-to-
reath pattern. We previously reported that this char-
cteristic trace is not always seen after lung transplan-
ation.18 Figure 1b shows one such measurement in a
atient whose exhaled NO was undetectable and the
race largely represents background noise. A similar
race was obtained in 8 of our 10 lung transplant
atients in this series. A fraction of the lung transplant
atients (2 of 10 patients in the current study), how-
ver, exhibited a similar NO profile to those undergoing
outine cardiac surgery. Figure 1c shows a representa-
ive trace from one of these patients.
We have also reported the pattern of GTN-induced
ncrease in exhaled NO in patients undergoing routine
eart surgery.24 As a reference, Figure 1a depicts such a
esponse in a patient undergoing bypass surgery before
PB. Figure 1b and c demonstrates that there is very little
hange in exhaled NO after GTN administration in lung
ransplant recipients when measured approximately 1
our after reperfusion during hemostatic and hemody-
amic stability. This response was not only missing in
hose patients whose basal NO was undetectable (Figure
c), but it was nearly abolished even in those who
emonstrated normal basal exhaled NO (Figure 1c).
Figure 2 shows summary data on basal and GTN-
nduced exhaled NO levels (Figure 2a: area under
urve; Figure 2b: peak levels). When compared with
ontrol levels in routine cardiac patients (CABG PRE),
asal levels of exhaled NO (both peak and area under
urve) were smaller after lung transplantation (TX).
emarkably, GTN-induced exhaled NO (measured as
ither peak or area under curve) was virtually elimi-
ated in the lung transplant group (0.4  0.3 vs 6.0 
.1 ppb and 2.4  4.6 vs 113.6  46.7 ppb, respec-
ively). Importantly, the influence of GTN bolus on
ystemic blood pressure was comparable to coronary
rtery bypass grafting (CABG; 38  3 and 9  2 mm Hg
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December 2007pectively). GTN-induced exhaled NO was also reduced
fter bypass (CABG POST, Figure 2), but not to the same
egree as after lung transplantation (2.2  0.7 and
6.4  7.3 ppb for peak and AUC, respectively).
A pilot study was conducted to investigate the kinet-
cs of recovery of GTN-induced exhaled NO response in
he post-operative period. Figure 3 depicts such an
xample in a ventilated lung transplant recipient. Al-
hough basal exhaled NO increased shortly after reper-
usion (4 to 24 hours), GTN remained without effect
uring this period and only partially recovered at 36
ours after the operation.
To determine whether exhaled NO dysfunction re-
ated to donor factors or ischemia–reperfusion (I/R)
njury, measurements were made in three acceptable
onors and in the recipients after implantation and
eperfusion of the lungs using the same analyzer and
ame ventilation setting. Figure 4a demonstrates a rep-
esentative pattern of exhaled NO in the accepted
































































































igure 1. Representative traces of gas-phase nitric oxide (NO) and
arbon dioxide (CO2) in response to intravenous administration of a
-g/kg bolus of nitroglycerin in patients undergoing open heart
urgery and lung transplantation. (a) Characteristic responses in a
ontrol patient before cardiopulmonary bypass. Panels (b) and (c)
epict endogenous and GTN-induced changes in representative lung
ransplant recipients with either reduced (b) or preserved (c) endoge-
ous exhaled NO levels. pharacteristic rapid rise after a breath-holding maneu-
er. Figure 4b depicts the donor response to GTN and
hows a response quite similar to those seen in control
ardiac patients. Figure 4c and d exhibits the situation
fter reperfusion in the recipient and shows that basal
xhaled NO and breath-hold NO was reduced and that
TN-induced exhaled NO response was practically
bsent.
igure 2. Endogenous (CTR) and nitroglycerin (GTN)-induced increase
n exhaled NO with regard to (a) area under the curve for 30 seconds
nd (b) peak levels in patients undergoing open heart surgery before
CABG PRE) and after cardiopulmonary bypass (CABG POST) and in
ung transplant recipients after reperfusion (TX POST). Data are
xpressed as mean SEM for CABG (n 10) and transplant (n 10).
igure 3. Kinetics of recovery of endogenous (basal) and nitroglycerin
GTN)-induced exhaled NO in a ventilated lung transplant recipient after
eperfusion. Note increased basal exhaled NO for 2 to 24 hours after
eperfusion, but detectable further response to GTN only at 36 hours.
s a reference, exhaled NO in the recipient’s native lungs (primary
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his study has demonstrated for the first time a pro-
ound and selective impairment in pulmonary metabo-
ism of GTN to increase exhaled NO in the setting of
rolonged and complete lung ischemia in humans.
hen compared with transient and partial ischemia,
uch as that occurring during cardiopulmonary bypass,
t appears that ischemia has a graded effect on exhaled
O pathways. Furthermore, GTN-induced exhaled NO
eems to be more severely affected than endogenous
xhaled NO. Our study also suggests that both endog-
nous- and exogenous-stimulus (GTN)-induced NO
athways can be preserved after brain death in poten-
ial multiple-organ donors and that the observed atten-
ation of NO pathways in the early post-operative
eriod is the effect of procurement/preservation/im-
lantation/reperfusion.
There are multiple dynamic pulmonary and systemic
nflammatory mechanisms that may influence exhaled
O during lung transplantation. I/R injury and surgery-






















































a                                                 
          
b                                                            
igure 4. Representative exhaled NO and CO2 traces before and after
efore and after a breath-holding maneuver (a) or after administration
entilated donor. The measurements were performed at a distant hosp
O analyzer (Logan Research, Inc.). Note characteristic exhaled NO tid
anels depict identical measurements after implantation and reperfusio
bsence of GTN response.ith a complicated picture of NOS expression and NO meneration and consumption. Therefore, actual NO
oncentrations will be different according to the dy-
amically changing cytokine environment, the nature
f microvascular and airway inflammation, neutrophil
ctivation, concomitant production of reactive oxygen
pecies, and acidity in the immediate environment of
ndothelial and airway epithelial cells.26
This study confirms and extends our previous hy-
othesis that exhaled NO may be considered as a
egative biomarker of acute lung injury.21,26 Indeed,
tudies of various cellular and animal models suggested
hat the dominant reaction of NO in the setting of
xidative stress and ischemia–reperfusion injury is con-
umption of NO.8,27,28 The potential clinical relevance
f this phenomenon to molecular diagnostics of lung
njury at the bedside has been implicated by demonstra-
ions that basal exhaled NO is attenuated to differing
egrees in bypass surgery, acute respiratory distress
yndrome (ARDS) and lung transplantation.18,19,29–32
ecause basal exhaled NO mainly reflects the relatively

















































1 hr post reperfusion
c
d
ng transplantation. Exhaled NO was measured under basal conditions
intravenous nitroglycerin (GTN, 3-g/kg bolus) (b) in a mechanically
l with standardized ventilation utilizing a portable chemiluminescence
races and increase after breath-holding and the GTN bolus. Right-side
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December 2007O might represent airway epithelial cell dysfunction
nd/or oxidative stress in the vicinity of these cells.24,26
To further investigate the fate of NO pathways in the
icrovascular lung compartment, one can deliver ex-
genous NO to the pulmonary circulation and monitor
volution of this NO in exhaled breath.18,23,35–37 We
ave suggested that GTN-induced exhaled NO might be
useful tool to monitor metabolic function of the
ulmonary microvasculature. This proposed test has
umerous clinical, diagnostic and mechanistic advan-
ages and could compliment the current clinical diag-
ostic efforts. It is clinically practical as the doses
dministered are routinely used in anesthesia and inten-
ive-care settings. The detection system is entirely non-
nvasive. There is good theoretical and biochemical
oundation for bioconversion of nitroglycerin to NO
nvolving cellular redox mechanism, thus linking oxida-
ive stress to alterations of GTN metabolism and NO
onsumption.38,39
Along these lines, we and others have demonstrated
hat routine cardiopulmonary bypass alters GTN metab-
lism to evoke exhaled NO.24,32,40 The major novel
nding of the current study is the complete loss of GTN
etabolism to produce exhaled NO in lungs subjected
o prolonged ischemia and reperfusion during lung
ransplantation. This phenomenon may be explained by
t least two major mechanisms: loss of enzyme activity
nd inactivation of NO.
Although the enzyme responsible for conversion of
TN to NO remains to be identified, the reaction
ppears to involve redox processes, particularly re-
uced cellular sulfhydrils.41 Because oxidant stress as-
ociated with I/R might have a significant influence on
his enzyme system, loss of the GTN-converting enzyme
ctivity could explain alterations in GTN-induced ex-
aled NO in lung transplant recipients.
Alternatively, NO produced by the activity of GTN-
onverting enzyme could be subjected to oxidant stress
nd consumption by fluid-phase reactions. This could
esult in a free radical reaction of NO with superoxide
nion to produce peroxynitrite, a mechanism impli-
ated in acute lung injury.42 Our findings that GTN-
nduced increase in exhaled NO is lost, even in patients
hose endogenous responses to produce exhaled NO
emains normal, suggests that altered GTN metabolism
robably represents vascular mechanisms rather than
vents in airway epithelial cells or interactions of NO in
he gas phase. Attenuation of GTN-induced responses
y oxidant stress has been reported before and in fact
as been postulated as the underlying mechanism of
oth primary and secondary nitrate tolerance.43,44 Our
tudy has extended these observations and suggests
hat monitoring GTN-induced exhaled NO could be
sed to assess primary and secondary nitrate tolerancen the clinical setting.37Although these observations clearly demonstrate pul-
onary microvascular injury during lung transplanta-
ion, the exact molecular mechanisms, the implications
o microvascular reactivity and endothelial permeabil-
ty, and overall clinical relevance remain to be uncov-
red. Our working hypothesis is that increased oxida-
ive stress is responsible for NO attenuation and the
ctivity of NO pathways could be restored by appropri-
te anti-oxidant therapy. We are currently testing this
ypothesis in model systems and in a clinical study
sing N-acetylcysteine.
We have suggested that decreased exhaled NO after
mplantation could be the result of reperfusion injury, but
rain death in the donor or preservation injury cannot be
uled out.18 Our study has provided initial evidence that
ccepted donors may have quasi-normal exhaled NO and
hat their responses to intravenous GTN do not seem to be
ifferent from those of control patients. It will be of
nterest to see if there are characteristic changes in
xhaled NO in unacceptable lung donors.
In conclusion, we have demonstrated for the first time
he dynamic alterations in NO pathways (as reflected in
xhaled NO arising from two pulmonary compartments)
hat may occur during the operative phase of the trans-
lantation process. Obtaining quantitative data on one of
he most powerful regulators of the inflammatory pro-
esses with relative ease and in real time at the bedside
ould be considered major progress. The data suggest that
he current practice of lung transplantation is associated
ith biochemical evidence of microvascular and airway
pithelial dysfunction in the immediate post-operative
eriod. Further studies are required to fully elucidate the
etails and clinical relevance of this phenomenon and the
iagnostic value of exhaled NO measurements in lung
ransplantation.
he authors thank the consultants, junior doctors and theatre
taff of Harefield Hospital and transplant coordinators for
upport and helpful discussions. Dr Marczin was recipient of
he MRC Clinician Scientist Fellowship during these studies.
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